Article Information
History
- May 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Sahar Saeed1,*,
- Sheila F. O’Brien1,2,
- Kento Abe3,4,
- QiLong Yi1,2,
- Bhavisha Rathod3,
- Jenny Wang3,
- Mahya Fazel-Zarandi3,
- Ashleigh Tuite5,
- David Fisman5,
- Heidi Wood6,
- Karen Colwill3,
- Anne-Claude Gingras3,4 and
- Steven Drews7,8,†
- 1Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Canada
- 2School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
- 3Lunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health System, Toronto, Canada
- 4Department of Molecular Genetics, University of Toronto, Toronto, Canada
- 5Dalla Lana School of Public Health, University of Toronto, Canada
- 6National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
- 7Microbiology Department, Canadian Blood Services, Ottawa, Canada
- 8Department of Laboratory Medicine & Pathology, Division of Diagnostic and Applied Microbiology, University of Alberta, Edmonton, Canada
Posted May 12, 2021.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard
